Publicaciones en las que colabora con Andrés Cervantes Ruiperez (8)

2021

  1. Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

    ESMO Open

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

  3. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

    Gynecologic Oncology, Vol. 152, Núm. 1, pp. 53-60

2013

  1. GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

    Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 509-525

2011

  1. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients A GEICO study

    International Journal of Gynecological Cancer, Vol. 21, Núm. 6, pp. 1048-1055

2007

  1. Treatment guidelines in ovarian cancer

    Clinical and Translational Oncology, Vol. 9, Núm. 5, pp. 308-316

2005

  1. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) study

    Annals of Oncology, Vol. 16, Núm. 5, pp. 749-755